Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMISE: Precision Therapies in Childhood and Adolescent Cancer
NCT06208657Phase 2Recruiting
- Sponsor
- Australia & New Zealand Children’s Haematology and Oncology Group
- Start
- Jul 2024
- Primary completion
- Dec 2030
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of paxalisib, relatlimab in childhood cancer, solid tumor, central nervous system tumor, lymphoma, sponsored by Australia & New Zealand Children’s Haematology and Oncology Group. Started Jul 2024; status: recruiting.
02
Drugs
paxalisibrelatlimab
03
Conditions
childhood cancersolid tumorcentral nervous system tumorlymphoma
Beyond the preview
Go deeper on NCT06208657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208657.